» Articles » PMID: 34573011

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes

Abstract

Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin ( = 40), liraglutide ( = 40), empagliflozin ( = 40), or their combination (GLP-1RA+SGLT-2i) ( = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups ( < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS ( < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (-8.76% and -9.83%) compared with insulin or SGLT2i (-0.5% and 3.22%), ( < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (-30.15% and -31.44%) compared with insulin or SGLT2i (4.72% and -3.74%), ( < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and -3.44%), ( < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment ( < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier.

Citing Articles

GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?.

Santulli G, Mone P, Varzideh F Future Cardiol. 2024; 21(1):5-8.

PMID: 39589856 PMC: 11812426. DOI: 10.1080/14796678.2024.2433381.


Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study.

Buldak L, Boldys A, Skudrzyk E, Machnik G, Okopien B Metabolites. 2024; 14(10).

PMID: 39452935 PMC: 11509483. DOI: 10.3390/metabo14100554.


Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model.

Rakic D, Jakovljevic V, Zivkovic V, Uzelac J, Jovic N, Muric M Pathophysiology. 2024; 31(4):559-582.

PMID: 39449523 PMC: 11503319. DOI: 10.3390/pathophysiology31040041.


Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.

Prentza V, Pavlidis G, Ikonomidis I, Pililis S, Lampsas S, Kountouri A J Clin Med. 2024; 13(19).

PMID: 39407846 PMC: 11476433. DOI: 10.3390/jcm13195786.


Cardiomodulatory Effects of Cardiometabolic and Antihyperglycemic Medications: The Roles of Oxidative and Endoplasmic Reticulum Stress.

Mooradian A Am J Cardiovasc Drugs. 2024; 25(1):37-46.

PMID: 39392561 DOI: 10.1007/s40256-024-00685-x.


References
1.
Zaibi N, Li P, Xu S . Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells. PLoS One. 2021; 16(2):e0247234. PMC: 7894948. DOI: 10.1371/journal.pone.0247234. View

2.
Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Patel H . Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease. Cardiovasc Hematol Agents Med Chem. 2018; 16(1):35-43. DOI: 10.2174/1871525716666180118152158. View

3.
Wilhelmi de Toledo F, Grundler F, Goutzourelas N, Tekos F, Vassi E, Mesnage R . Influence of Long-Term Fasting on Blood Redox Status in Humans. Antioxidants (Basel). 2020; 9(6). PMC: 7346198. DOI: 10.3390/antiox9060496. View

4.
Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S . Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016; 15(1):157. PMC: 5106779. DOI: 10.1186/s12933-016-0473-7. View

5.
Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S . Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2019; 317(4):G508-G517. DOI: 10.1152/ajpgi.00139.2019. View